AI assistant
STANDARD BIOTOOLS INC. — Director's Dealing 2024
Mar 7, 2024
32853_dirs_2024-03-06_f9e75518-d071-4b99-b1c2-013a4b3c3512.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-03-04
Reporting Person: Casdin Partners Master Fund, L.P. (Director, 10% Owner)
Reporting Person: Casdin Capital, LLC (Director, 10% Owner)
Reporting Person: Casdin Partners GP, LLC (Director, 10% Owner)
Reporting Person: Casdin Private Growth Equity Fund II, L.P. (Director)
Reporting Person: Casdin Private Growth Equity Fund II GP, LLC (Director)
Reporting Person: Casdin Partners FO1-MSV, LP (Director)
Reporting Person: Casdin Private Growth Equity Fund, L.P. (Director)
Reporting Person: CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (Director)
Reporting Person: Casdin Eli (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-04 | Common Stock | P | 250000 | $2.57 | Acquired | 11496525 | Direct |
| 2024-03-05 | Common Stock | P | 1403 | $2.615 | Acquired | 11497928 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 103556 | Direct |
| Common Stock | 2744219 | Indirect |
| Common Stock | 1200000 | Indirect |
| Common Stock | 7548000 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F3: The securities are owned directly by Eli Casdin.
F4: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F5: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F6: The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.